Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
BMJ Open
|
December 9, 2023
Application of ventilator-associated events (VAE) in ventilator-associated pneumonia (VAP) notified in Brazil (IMPACTO MR-PAV): a protocol for a cohort study
Giovanna Marssola Nascimento, Daniela Laranja Gomes Rodrigues, Daniela Ghidetti Mangas Catarino, et al.
Lancet Regional Health. Americas
|
November 7, 2024
Teleconsultation on patients with type 2 diabetes in the Brazilian public health system: a randomised, pragmatic, open-label, phase 2, non-inferiority trial (TELECONSULTA diabetes trial)
Daniela Laranja Gomes Rodrigues, Gisele Silvestre Belber, Frederica Valle de Queiroz Padilha, et al.
Vaccine
|
June 21, 2022
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis
Thays Zanon Casagrande, Ismael Artur da Costa-Rocha, Maria Bernadete Renoldi de Oliveira Gavi, et al.
Scientific Reports
|
May 18, 2021
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination
Ismael Artur da Costa-Rocha, Ketty Lysie Libardi Lira Machado, Ana Carolina Campi-Azevedo, et al.
Vaccines
|
September 28, 2024
Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study
Débora Cerqueira Calderaro, Valéria Valim, Gilda Aparecida Ferreira, et al.
Vaccines
|
January 8, 2025
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
Ketty Lysie Libardi Lira Machado, Ana Paula Neves Burian, Olindo Assis Martins-Filho, et al.
Frontiers in Immunology
|
August 9, 2020
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
Valéria Valim, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Vaccines
|
November 26, 2025
Third Booster Half Dose of ChAdOx1-nCov-19 Is Effective, Safe, and Induces Long-Duration Humoral and Cellular Immune Response to Omicron: 1-Year Follow-Up of Viana Study
Nésio Fernandes de Medeiros-Junior, Maria da Penha Gomes Gouvea, Luiz Antônio Bastos Camacho, et al.
Vaccines
|
February 26, 2025
Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study
Natália Sarzi Sartori, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Vaccines
|
October 28, 2025
Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study
Natália Sarzi Sartori, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
BMJ Open
|
December 9, 2023
Application of ventilator-associated events (VAE) in ventilator-associated pneumonia (VAP) notified in Brazil (IMPACTO MR-PAV): a protocol for a cohort study
Giovanna Marssola Nascimento, Daniela Laranja Gomes Rodrigues, Daniela Ghidetti Mangas Catarino, et al.
Lancet Regional Health. Americas
|
November 7, 2024
Teleconsultation on patients with type 2 diabetes in the Brazilian public health system: a randomised, pragmatic, open-label, phase 2, non-inferiority trial (TELECONSULTA diabetes trial)
Daniela Laranja Gomes Rodrigues, Gisele Silvestre Belber, Frederica Valle de Queiroz Padilha, et al.
Vaccine
|
June 21, 2022
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis
Thays Zanon Casagrande, Ismael Artur da Costa-Rocha, Maria Bernadete Renoldi de Oliveira Gavi, et al.
Scientific Reports
|
May 18, 2021
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination
Ismael Artur da Costa-Rocha, Ketty Lysie Libardi Lira Machado, Ana Carolina Campi-Azevedo, et al.
Vaccines
|
September 28, 2024
Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study
Débora Cerqueira Calderaro, Valéria Valim, Gilda Aparecida Ferreira, et al.
Vaccines
|
January 8, 2025
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
Ketty Lysie Libardi Lira Machado, Ana Paula Neves Burian, Olindo Assis Martins-Filho, et al.
Frontiers in Immunology
|
August 9, 2020
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
Valéria Valim, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Vaccines
|
November 26, 2025
Third Booster Half Dose of ChAdOx1-nCov-19 Is Effective, Safe, and Induces Long-Duration Humoral and Cellular Immune Response to Omicron: 1-Year Follow-Up of Viana Study
Nésio Fernandes de Medeiros-Junior, Maria da Penha Gomes Gouvea, Luiz Antônio Bastos Camacho, et al.
Vaccines
|
February 26, 2025
Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study
Natália Sarzi Sartori, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Vaccines
|
October 28, 2025
Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study
Natália Sarzi Sartori, Ketty Lysie Libardi Lira Machado, Samira Tatiyama Miyamoto, et al.
Page
of 6